Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

INTRODUCTION: Onabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatment of chronic migraine (CM), a highly disabling disorder. Although treatment response varies among patients, current guidelines suggest to stop treatment after cycle 2 if no response is achieved. Th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Neurol
Hlavní autoři: Sarchielli, Paola, Romoli, Michele, Corbelli, Ilenia, Bernetti, Laura, Verzina, Angela, Brahimi, Elona, Eusebi, Paolo, Caproni, Stefano, Calabresi, Paolo
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2017
Témata:
Neuroscience
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723003/
https://ncbi.nlm.nih.gov/pubmed/29255444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2017.00655
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky